Benzodiazepines in Cancer Patients: Uses and Indications

Primary Indications

• The National Comprehensive Cancer Network recommends benzodiazepines for refractory insomnia in cancer patients, with short-acting options like lorazepam being preferred 1
• Sleep disturbances affect approximately 75% of patients with advanced cancer, making this a common indication for benzodiazepine therapy 1

Anxiety Management

• The American Society of Clinical Oncology indicates that benzodiazepines are indicated for moderate to severe anxiety in cancer patients, particularly when rapid symptom control is needed 2
• They should be used as part of a comprehensive approach that addresses underlying medical causes of anxiety first, with caution warranted regarding long-term use due to increased risk of abuse, dependence, and adverse effects including cognitive impairment 2

Delirium Management

• The National Comprehensive Cancer Network suggests that benzodiazepines like lorazepam may be added for agitation that is refractory to high doses of neuroleptics in patients with severe delirium 3
• Lorazepam can be used at doses of 1 mg subcutaneously or intravenously (up to 2 mg maximum) for severe agitation in delirious cancer patients 4

Dosing Considerations

• In elderly or frail patients, lower doses of benzodiazepines should be used due to increased risk of falls, cognitive impairment, and other adverse effects 4
• Midazolam can be administered at 2.5 mg subcutaneously or intravenously every hour as needed (up to 5 mg maximum) for severe agitation 4

Important Precautions

• The National Comprehensive Cancer Network advises that benzodiazepines should be avoided in older patients and those with cognitive impairment due to risk of worsening confusion 1
• Caution is needed when combining benzodiazepines with olanzapine due to risk of oversedation and respiratory depression 4
• Benzodiazepines can themselves cause increased patient agitation and delirium in some cases, and should be used with caution in patients with severe pulmonary insufficiency, severe liver disease, or myasthenia gravis 4

Monitoring and Follow-up

• Regular assessment of treatment response and adverse effects is essential, with consideration of tapering benzodiazepines if symptoms are under control and primary sources of anxiety are no longer present 5
• Longer periods of tapering are often necessary, particularly with potent or rapidly eliminated medications, and alternative interventions should be considered after 8 weeks of treatment if symptom reduction is poor despite good compliance 5

Management of Cancer-Related Anxiety with Benzodiazepines

Primary Recommendation: Lorazepam

• The European Society for Medical Oncology recommends lorazepam as the preferred benzodiazepine for cancer-related anxiety, typically dosed at 0.5-1.0 mg every 6-8 hours orally or sublingually, due to its intermediate half-life and multiple routes of administration 6
• Lorazepam has no active metabolites, making it safer in patients with hepatic impairment, and its starting dose allows for careful titration 6

When to Use Midazolam Instead

• The European Society for Medical Oncology guidelines recommend midazolam for far advanced stages and dying patients, particularly when anxiety is accompanied by severe dyspnea or agitation, with a dosing of 2.5-5 mg subcutaneously every 4 hours 6
• Midazolam has a rapid onset, making it ideal for acute severe symptoms, and can be used in combination with opioids for terminal dyspnea and anxiety 6

Critical Time-Limited Use Principle

• The American Society of Clinical Oncology explicitly states that all benzodiazepines must be used for limited duration only, due to significant risks of dependence, withdrawal, and cognitive impairment 7
• Benzodiazepines should be used as bridge therapy only while waiting for SSRI/SNRI therapeutic effect, and tapering should begin once SSRI/SNRI reaches therapeutic effect 7

Special Clinical Situations

• For anxiety accompanying dyspnea, benzodiazepines should be added only after opioids have been optimized, as they predominantly reduce the unpleasantness of dyspnea rather than treating the underlying cause 6
• The combination of opioids plus benzodiazepines is appropriate in advanced disease 6

Monitoring Requirements

• Monthly assessment is mandatory until symptoms subside, including compliance with medication, satisfaction with symptom relief, adverse effects, and consideration of tapering if symptoms are controlled 7